Neuroprotection of Pioglitazone in Acute Ischemic Stroke

Recruiting

Phase 2 Results N/A

Summary of Purpose

Pioglitzone, an oral anti-diabetic drug which can reduce insulin resistance and decrease inflammation. It has been proven to be an effective neuroprotective agent in animal model of ischemic stroke. In this study, the investigators will conduct a phase II clinical trial (double-blind, randomized placebo controlled study) to survey the neuroprotection effect of pioglitazone in stroke patients with hyperglycemia. A...

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 19 April 2016.

1 Jul 2014 14 Jul 2014 1 Jul 2016 1 Jul 2016 1 Apr 2016 Unavailable
Start Date First Received 1st Completion Completion Verification Results

Trial Basics

Interventions

Conditions

Sponsors

Trial Design

  • Allocation: Randomized
  • Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
  • Purpose: Treatment
  • Endpoint: Efficacy Study
  • Intervention: Parallel Assignment

Contacts

  • Nai-Fang Chi, MD

    +886970746959